Merck Initiates Phase III Study For Stimuvax
Merck KGaA (Merck) has initiated multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.